Clinical Trial Update: Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pegcrisantaspase in combination with venetoclax for relapsed or refractory acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Acute Myeloid Leukemia

Drugs mentioned

• Pegcrisantaspase (Pegcrisantaspase)
• Venetoclax (venetoclax)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED